New research indicates that even after successful treatment completion, tuberculosis patients experience higher rates of death from respiratory and cardiovascular causes.1
RT’s Three Key Takeaways:
Extended Survival Risk: TB survivors face a significantly higher risk of death from natural causes for up to 14 years after diagnosis and treatment completion.
Broad Health Impact: The increased mortality risk affects multiple systems, with significantly higher rates of death from respiratory, cardiovascular, and endocrine causes.
Clinical Monitoring Gap: Researchers recommend that healthcare providers implement long-term follow-up protocols, including lung function and cardiovascular screenings, to address the lasting effects of the disease.
Individuals who survive tuberculosis (TB) remain at a significantly elevated risk of death for at least 14 years after diagnosis and successful treatment, according to a study published in Nature Medicine.1
The study, which analyzed data from the 100 Million Brazilian Cohort between 2004 and 2018, matched 185,921 individuals diagnosed with TB and 111,871 who successfully completed treatment with TB-free counterparts.1 The researchers found that those in the diagnosed cohort had a natural cause mortality risk ratio (RR) of 2.16 at the end of 14 years. Natural causes were defined as deaths excluding TB, human immunodeficiency virus (HIV), and external causes.1
Even for those who successfully completed treatment, the risk of death remained 1.77 times higher than the unexposed group over the 14-year follow-up period.1
Long-term Respiratory and Cardiovascular Impact
The data showed that TB survivors experience excess mortality across multiple organ systems. Respiratory-related deaths showed a particularly high risk early in the follow-up period. In the treated cohort, the one-year RR for respiratory deaths was 6.15.1
The study also identified elevated risks for cardiovascular, endocrine, and cancer-related mortality.1 Specifically, cardiovascular deaths remained a significant risk for more than a decade post-diagnosis.1 The researchers noted that chronic inflammation from TB might exacerbate metabolic dysregulation, contributing to endocrine-related deaths.1
“Our findings reveal that individuals successfully treated for TB still experience excess mortality across multiple organ systems and causes, highlighting the lasting impact of TB on overall health,” the researchers stated in the study.1
Addressing the Policy Gap
Current World Health Organization (WHO) guidelines focus primarily on the diagnosis and bacteriological cure of active disease.1 However, the study authors argued that a “complete return to health” is not guaranteed by a cure of the active infection alone.1
The authors suggested that the current approach overlooks the long-term health consequences of the disease, such as lasting lung damage and chronic inflammation.1 They advocated for the integration of post-TB assessments into national management guidelines.1
“Integrating post-TB assessments, such as lung function testing, cardiovascular risk screening, and cancer surveillance, into national guidelines for post-TB management is essential,” the researchers stated.1
Socioeconomic Factors and Comorbidities
The study also examined the impact of comorbidities, finding that the absolute excess mortality in patients with both TB and diabetes mellitus was substantially larger than in those with TB and HIV.1
While the researchers acknowledged that poverty and social vulnerability contribute to TB risk, they found that the excess risk of death among patients far exceeded the risk found among household contacts.1 This suggests that the increased mortality after TB treatment cannot be attributed solely to socioeconomic conditions.1
The researchers concluded that increased awareness among healthcare professionals regarding post-TB complications is necessary to ensure timely management and more patient-centered care.1
Reference
Cerqueira-Silva, T., Boaventura, V.S., Paixão, E.S. et al. Long-term risk of death after tuberculosis diagnosis and treatment. Nat Med (2026). https://doi.org/10.1038/s41591-026-04294-w